Human IFN-gamma SARS-CoV-2 ELISpotPLUS kit (HRP), pre-coated strip plates from MABTECH AB
Search, find, compare suppliers for Human IFN-gamma SARS-CoV-2 ELISpotPLUS kit (HRP), pre-coated strip plates products.
| Edit | |
|---|---|
| Product Name | Human IFN-gamma SARS-CoV-2 ELISpotPLUS kit (HRP), pre-coated strip plates |
| Description | This kit is ideal for users who want a convenient and sensitive assay. The assay is designed for the enumeration of cells secreting human IFN-γ in response to SARS-CoV-2 peptides. The kit includes one ELISpot strip plate pre-coated with monoclonal antibody, SARS-CoV-2 S1 scanning pool, SARS-CoV-2 S2 N defined peptide pool, SARS-CoV-2 S N M O defined peptide pool, biotinylated detection antibody, Streptavidin-HRP and ready-to-use TMB substrate. A polyclonal activator for human T cells (mAb CD3-2) is supplied as a positive control for cytokine secretion. Pre-coated plates reduce assay time and minimize variability. In addition, strip-plates are ideal when running a limited number of wells. |
| Size | 1 plate |
| Concentration | n/a |
| Applications | ELISpot |
| Other Names | ELISpot kit, assay, EIA, ELISA, enzyme immunoassay |
| Gene, Accession, CAS # | Gene ID: 3458 |
| Catalog # | 3420-4HST-P1-1 |
| Price | please inquire |
| Order / More Info | Human IFN-gamma SARS-CoV-2 ELISpotPLUS kit (HRP), pre-coated strip plates from MABTECH AB |
| Product Specific References | Gubin, M. M., et al. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. (http://www.ncbi.nlm.nih.gov/pubmed/25428507)Sekine, T., et al. (2020). Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. (http://www.ncbi.nlm.nih.gov/pubmed/32979941)Czerkinsky, C., et al. (1988). Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. Journal of immunological methods. (http://www.ncbi.nlm.nih.gov/pubmed/3131436)Zacharakis, N., et al. (2018). Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nature medicine. (http://www.ncbi.nlm.nih.gov/pubmed/29867227)Ott, P. A., et al. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. (http://www.ncbi.nlm.nih.gov/pubmed/28678778) |
MABTECH AB
MABTECH AB
Box 1233
SE-131 28 Nacka Strand SWEDEN
P: +46 8 716 27 00
F: +46 8 716 27 01
mabtech@mabtech.com
http://www.mabtech.com
Profile of MABTECH AB
Return to Products